Activaero Gmbh Research & Development

Pari Pharma Gmbh

Vectura Gmbh

Erasmus Mc-sophia Children's Hospital

Philipp Kroneberg

Thomas Hofmann

Bernard Muellinger

Gerhard Scheuch

Michael Hahn

Sascha Roeder

Carola Fuchs

Matthias Finke

Edgard Osswald

Björn Eschrich

Ingo Schraut

Marije Van Den Beukel-Bakker

Bernhard MÜLLINGER

Harm A W N Tiddens

Marion Wencker

The present invention relates to a control device for controlling an operation of an aerosol nebulizer system (), said aerosol nebulizer system () comprising an aerosol generator () for nebulizing a liquid and a plurality of sensor units (), said control device () comprising: a communication unit (), configured to establish a wireless communication connection and to perform data transmission with the aerosol nebulizer system (), a sensor data control unit (), configured to trigger a selection of sensor data related to the sensor units () to be wirelessly transmitted to the control device ().

Control device for aerosol nebulizer system

A drug and device combination system used in a method for treatment of patients suffering from severe and oral corticosteroid-dependent asthma and other respiratory diseases requiring a treatment with orally administered steroids. The method for administration of the inhalable corticosteroid by a flow rate and volume regulated inhalation. The combination system of the inhalable corticosteroid and the device for regulating flow rate and volume of the inhalable corticosteroid and thus achieving delivery of said inhalable corticosteroid into the small airways of the lungs. The individually programmable device that assures safe and reproducible corticosteroid delivery compliant with treatment protocol.

Flow and volume regulated inhalation for treatment of severe oral corticosteroid-dependent asthma

Methods, devices and compositions for treatment of severe and uncontrolled asthma are provided by which high amounts of an inhaled corticosteroid are directed to the small airways of the lower lungs. The invention provides for a substantial decrease in the dose of concurrently administered oral corticosteroids. A particular advantage of the invention is the significant reduction in corticosteroid-related adverse effects.

Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma

Growing community of inventors

Olching, Germany

Philipp Kroneberg